121 related articles for article (PubMed ID: 31748757)
21. Dynamics of SOX2 and CDX2 Expression in Barrett's Mucosa.
Barros R; Pereira D; Callé C; Camilo V; Cunha AI; David L; Almeida R; Dias-Pereira A; Chaves P
Dis Markers; 2016; 2016():1532791. PubMed ID: 27766003
[TBL] [Abstract][Full Text] [Related]
22. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
23. Primary Endometrial Yolk Sac Tumor With Endodermal-Intestinal Differentiation Masquerading as Metastatic Colorectal Adenocarcinoma.
Damato S; Haldar K; McCluggage WG
Int J Gynecol Pathol; 2016 Jul; 35(4):316-20. PubMed ID: 26598980
[TBL] [Abstract][Full Text] [Related]
24. A case of nasal low-grade non-intestinal-type adenocarcinoma with aberrant CDX2 expression and a novel SYN2-PPARG gene fusion in a 13-year-old girl.
Soon GST; Chang KTE; Kuick CH; Petersson F
Virchows Arch; 2019 May; 474(5):619-623. PubMed ID: 30666415
[TBL] [Abstract][Full Text] [Related]
25. TTF-1, napsin A and CDX2 co-expression in metastatic rectal adenocarcinoma to the lung.
Li W; Cohen MB
Cytopathology; 2021 Jan; 32(1):146-148. PubMed ID: 32633432
[No Abstract] [Full Text] [Related]
26. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
27. CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's Disease.
Lora V; Kanitakis J
Anticancer Res; 2009 Dec; 29(12):5033-7. PubMed ID: 20044613
[TBL] [Abstract][Full Text] [Related]
28. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
[TBL] [Abstract][Full Text] [Related]
29. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
30. Altered expression of CDX2 in colorectal cancers.
Choi BJ; Kim CJ; Cho YG; Song JH; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY; Park WS
APMIS; 2006 Jan; 114(1):50-4. PubMed ID: 16499661
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
32. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.
Lopes N; Bergsland C; Bruun J; Bjørnslett M; Vieira AF; Mesquita P; Pinto R; Gomes R; Cavadas B; Bennett E; Pereira L; Lothe RA; Almeida R; David L
Gastric Cancer; 2020 Sep; 23(5):811-823. PubMed ID: 32215766
[TBL] [Abstract][Full Text] [Related]
33. CDX2 expression and perioperative patient serum affects the adhesion properties of cultured colon cancer cells.
Davidsen J; Jessen SB; Watt SK; Larsen S; Dahlgaard K; Kirkegaard T; Gögenur I; Troelsen JT
BMC Cancer; 2020 May; 20(1):426. PubMed ID: 32408894
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study.
Seipel AH; Samaratunga H; Delahunt B; Wiklund P; Clements M; Egevad L
APMIS; 2016 Apr; 124(4):263-70. PubMed ID: 26778368
[TBL] [Abstract][Full Text] [Related]
35. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
Tot T
Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
[TBL] [Abstract][Full Text] [Related]
36. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
37. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas.
Yatabe Y; Koga T; Mitsudomi T; Takahashi T
J Pathol; 2004 Jun; 203(2):645-52. PubMed ID: 15141379
[TBL] [Abstract][Full Text] [Related]
38. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
39. Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry.
Owens CL; Epstein JI; Netto GJ
Arch Pathol Lab Med; 2007 Apr; 131(4):599-603. PubMed ID: 17425391
[TBL] [Abstract][Full Text] [Related]
40. CDX2 as a prognostic marker in gastric cancer.
Masood MA; Loya A; Yusuf MA
Acta Gastroenterol Belg; 2016; 79(2):197-200. PubMed ID: 27382937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
